Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 7. Distribution of time-dependent inhibitor positive and negative compounds among Novartis (A) marketed drugs and (B) new chemical entities (i.e., drug candidates). The dark gray fraction represents strong (“high”) reversible inhibition (Zimmerlin et al., 2011). Reprinted from Drug Metab. Dispos., Vol. 39, Zimmerlin, A., Trunzer, M. and Faller, B., CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs, pages 1039-1046 (Zimmerlin et al., 2011), Copyright (2011), with permission from American Society for Pharmacology and Experimental Therapeutics.
Biomolecules & Therapeutics 2022;30:1~18
© Biomolecules & Therapeutics